We live for science to develop life-changing medicines and improve the treatment of diseases.
With our innovative medicines, we enable the treatment of four out of the five deadliest diseases.
AstraZeneca makes an indispensable contribution to the treatment of patients in a wide range of therapeutic areas
Through the acquisition of Alexion (completed in 2021), AstraZeneca has also entered the area of rare diseases.
In each of these therapeutic areas, AstraZeneca does not only offer new medicines and innovative technological solutions, but it also aims to contribute to:
- Spreading more awareness about diseases
- Expanding the skills of healthcare professionals
- Increasing attention towards prevention, and strengthening doctor-patient relationships
- Improve patients’ journey, from the diagnosis to the tackling of diseases
The therapeutic areas in which AstraZeneca is active are among the most impactful in terms of mortality, quality of life and healthcare system costs.
Top 5 causes of death* in Austria, 2023
* The ranking refers to non-communicable diseases and was extraced from the data of Statistik Austria (Gestorbene 2023_nach Todesursachen, Alter und Geschlecht)
Top 5 pathologies in terms of seriousness** in Austria, 2021
**Measured in terms of DALYs, i.e. Disability-Adjusted Life Years
Together, these diseases caused about 66% of deaths (~59,500 in 2023) and were collectively responsible for ~41% of DALYs (Disability-Adjusted Life Years) and ~15% of YLDs (Years Lived with Disability) in 2021.
Sources: The European House – Ambrosetti elaboration of AstraZeneca Österreich, 2023. Updated 2025.| „Gestorbene 2023_nach Todesursachen, Alter und Geschlecht“; Statistik Austria, last accessed 18.02.2025 | VizHub - GBD Compare (https://vizhub.healthdata.org/gbd-compare/), last accessed 18.02.2025